News

• Abbott Declares 405th Consecutive Quarterly Dividend
• Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
• Abbott Hosts Conference Call for First-Quarter Earnings
• Abbott Hosts Conference Call for Fourth-Quarter Earnings
• Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
• Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
• Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
• Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
• Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
• Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
• Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent
• Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
• Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
• MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
• New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
• New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve